Literature DB >> 26392511

Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.

Zahra Kassamali1, Randall A Prince2, Larry H Danziger3, John C Rotschafer4, Paul R Rhomberg5, Ronald N Jones5.   

Abstract

We investigated the antimicrobial activity of four polymyxin B components, B1, B2, B3, and isoleucine (Ile)-B1, individually and in combination. B3 was the most active agent against all organisms tested except Acinetobacter baumannii, for which Ile-B1 was most active. One combination met the criteria for synergy, B3 plus Ile-B1. No combinations exhibited antagonism. The dominant components of polymyxin B products (B1 and B2) were associated with the lowest probability of improved antibacterial activity when combined.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26392511      PMCID： PMC4649206          DOI： 10.1128/AAC.01021-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Liquid chromatography of polymyxin B sulphate.

Authors:  J A Orwa; A Van Gerven; E Roets; J Hoogmartens
Journal:  J Chromatogr A       Date:  2000-02-18       Impact factor: 4.759

Review 2.  Polymyxins: wisdom does not always come with age.

Authors:  Zahra Kassamali; John C Rotschafer; Ronald N Jones; Randall A Prince; Larry H Danziger
Journal:  Clin Infect Dis       Date:  2013-07-11       Impact factor: 9.079

3.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

4.  Variability of polymyxin B major components in commercial formulations.

Authors:  Jie He; Kimberly R Ledesma; Wai-Ying Lam; Deborah A Figueroa; Tze-Peng Lim; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2009-12-31       Impact factor: 5.283

5.  Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin.

Authors:  Helio S Sader; Paul R Rhomberg; Robert K Flamm; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-25       Impact factor: 2.803

6.  Isolation and structural characterization of polymyxin B components.

Authors:  J A Orwa; C Govaerts; R Busson; E Roets; A Van Schepdael; J Hoogmartens
Journal:  J Chromatogr A       Date:  2001-04-06       Impact factor: 4.759

7.  Pharmacokinetics and renal disposition of polymyxin B in an animal model.

Authors:  Kamilia Abdelraouf; Jie He; Kimberly R Ledesma; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

8.  Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli.

Authors:  Janet A Hindler; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

9.  Pharmacokinetics of intravenous polymyxin B in critically ill patients.

Authors:  Alexandre P Zavascki; Luciano Z Goldani; Guoying Cao; Silvana V Superti; Larissa Lutz; Afonso L Barth; Fabiano Ramos; Márcio M Boniatti; Roger L Nation; Jian Li
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

10.  In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.

Authors:  Ronald N Jones; Thomas R Fritsche; Gary J Moet
Journal:  Diagn Microbiol Infect Dis       Date:  2008-01-24       Impact factor: 2.803
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.